TSHA241115P1500
- 0.05
- 0.000.00%
Taysha Gene Therapies Newsroom
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Optimism for Taysha Gene Therapies: Promising Preclinical Data and Upcoming Catalysts Drive Buy Rating
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Taysha Gene Therapies To Present Biodistribution Data From An Analysis Evaluating AAV9 Gene Therapy Delivery At The Upcoming 31st Annual ESGCT Congress
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
Express News | Taysha Gene Therapies Announces Oral Presentation on Tsha-102 in Rett Syndrome at Upcoming 9TH World Rett Syndrome Congress
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.4% and a total average return of 20.8%
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
BMO Capital analyst Keith Tapper CFA maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 80
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7
On Aug 14, major Wall Street analysts update their ratings for $Taysha Gene Therapies(TSHA.US)$, with price targets ranging from $5 to $7.BMO Capital analyst Keith Tapper CFA maintains with a buy
Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Taysha Gene Therapies Analyst Ratings
Maintained Buy Rating on Taysha Gene Therapies Amid Progress and Solid Financials
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Buy Rating Affirmed for Taysha Gene Therapies Amid Strong Financials and Promising Clinical Trials
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $8
On Aug 13, major Wall Street analysts update their ratings for $Taysha Gene Therapies(TSHA.US)$, with price targets ranging from $5 to $8.Wells Fargo analyst Yanan Zhu maintains with a buy rating,
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)